Commense Bio has filed a notice of an exempt offering of securities to raise $2,671,875.00 in New Funding.
According to filings with the U.S. Securities and Exchange Commission, Commense Bio is raising up to $2,671,875.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Commense Bio
Commense Bio is a biopharmaceutical company committed to developing and delivering transformative therapeutics for patients suffering from invasive infections with a significant unmet need. Our proprietary technology has the potential to unlock the next generation of bacterial therapeutics. Commense Bio is utilizing differentiated synthetic biology to engineer optimized bacterial strains and deliver novel therapeutics. Our innovative Safety Switched strains mimic nature and use bacterial interference to prevent invasive infections. At Commense Bio, we are applying our broad IP Platform across multiple infectious diseases as we strive to establish new, transformative standards of care.
To learn more, visit https://commensebio.com/
LinkedIn: https://www.linkedin.com/company/commense-bio/
Contact:
Judith Boice, Chief Executive Officer
https://www.linkedin.com/in/judith-boice-1664867/
SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.
